Baricitinib for the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food an...
Saved in:
Main Authors: | Ivan Urits, Jacob Israel, Hayk Hakobyan, George Yusin, Grace Lassiter, Nathan Fackler, Amnon A. Berger, Hisham Kassem, Alan Kaye, Omar Viswanath |
---|---|
Format: | article |
Language: | EN |
Published: |
Termedia Publishing House
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/efa1b6f0f94641f0bc847beee18fbe9b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021) -
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019) -
Management of Rheumatoid Arthritis: An Overview
by: Andrei-Flavius Radu, et al.
Published: (2021) -
Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos
by: Quera,Rodrigo, et al.
Published: (2020) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
by: Gordon D, et al.
Published: (2021)